• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大规模平行分析 HIV-1 对融合抑制剂恩夫韦肽的耐药性。

Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide.

机构信息

Basic Sciences and Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

出版信息

Viruses. 2019 May 15;11(5):439. doi: 10.3390/v11050439.

DOI:10.3390/v11050439
PMID:31096572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6563210/
Abstract

Identifying drug resistance mutations is important for the clinical use of antivirals and can help define both a drug's mechanism of action and the mechanistic basis of resistance. Resistance mutations are often identified one-at-a-time by studying viral evolution within treated patients or during viral growth in the presence of a drug in cell culture. Such approaches have previously mapped resistance to enfuvirtide, the only clinically approved HIV-1 fusion inhibitor, to enfuvirtide's binding site in the N-terminal heptad repeat (NHR) of the Envelope (Env) transmembrane domain as well as a limited number of allosteric sites. Here, we sought to better delineate the genotypic determinants of resistance throughout Env. We used deep mutational scanning to quantify the effect of all single-amino-acid mutations to the subtype A BG505 Env on resistance to enfuvirtide. We identified both previously characterized and numerous novel resistance mutations in the NHR. Additional resistance mutations clustered in other regions of Env conformational intermediates, suggesting they may act during different fusion steps by altering fusion kinetics and/or exposure of the enfuvirtide binding site. This complete map of resistance sheds light on the diverse mechanisms of enfuvirtide resistance and highlights the utility of using deep mutational scanning to comprehensively map potential drug resistance mutations.

摘要

鉴定耐药突变对于抗病毒药物的临床应用非常重要,有助于确定药物的作用机制和耐药的机制基础。耐药突变通常通过研究治疗患者体内病毒的进化或在细胞培养中药物存在下病毒的生长来逐个鉴定。这些方法先前已经将对 enfuvirtide 的耐药性定位到 HIV-1 融合抑制剂 enfuvirtide 的 N 端七肽重复(NHR)结合位点以及少数变构位点, enfuvirtide 是唯一经临床批准的 HIV-1 融合抑制剂。在这里,我们试图更详细地描绘整个 Env 中耐药的基因型决定因素。我们使用深度突变扫描来量化对亚型 A BG505 Env 的所有单个氨基酸突变对 enfuvirtide 耐药性的影响。我们鉴定了 NHR 中以前表征的和许多新的耐药突变。其他耐药突变聚集在 Env 构象中间体的其他区域,表明它们可能通过改变融合动力学和/或暴露 enfuvirtide 结合位点来在不同的融合步骤中起作用。这种完整的耐药图谱阐明了 enfuvirtide 耐药的多种机制,并强调了使用深度突变扫描全面绘制潜在耐药突变的实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81db/6563210/302485a8fc04/viruses-11-00439-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81db/6563210/57b6e51609b5/viruses-11-00439-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81db/6563210/e75f3b9074d8/viruses-11-00439-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81db/6563210/302485a8fc04/viruses-11-00439-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81db/6563210/57b6e51609b5/viruses-11-00439-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81db/6563210/e75f3b9074d8/viruses-11-00439-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81db/6563210/302485a8fc04/viruses-11-00439-g003.jpg

相似文献

1
Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide.大规模平行分析 HIV-1 对融合抑制剂恩夫韦肽的耐药性。
Viruses. 2019 May 15;11(5):439. doi: 10.3390/v11050439.
2
Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.HIV-1 env 基因区 HR1-HR2 以外区域对融合抑制剂恩夫韦肽耐药性和临床分离株病毒感染力的影响。
PLoS One. 2011;6(7):e21535. doi: 10.1371/journal.pone.0021535. Epub 2011 Jul 8.
3
Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.HIV-1 包膜糖蛋白 N 端七肽重复区中 Glu560 的突变有助于抵抗病毒进入的肽抑制剂。
Retrovirology. 2019 Dec 3;16(1):36. doi: 10.1186/s12977-019-0496-8.
4
Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.突变增加了 HIV-1 包膜糖蛋白 gp41 的融合后构象稳定性,被 X4 和 R5 HIV-1 病毒选择以逃避针对 gp41 七肽重复 1 的融合抑制剂,但两种病毒的 gp120 适应性突变不同。
J Virol. 2019 May 15;93(11). doi: 10.1128/JVI.00142-19. Print 2019 Jun 1.
5
Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.HIV-1对靶向Gp41口袋的短肽融合抑制剂的耐药机制
J Virol. 2015 Jun;89(11):5801-11. doi: 10.1128/JVI.00373-15. Epub 2015 Mar 18.
6
Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.人类免疫缺陷病毒1型对融合抑制剂恩夫韦肽和T-649基线易感性的决定因素位于肽相互作用位点之外。
J Virol. 2004 Jul;78(14):7582-9. doi: 10.1128/JVI.78.14.7582-7589.2004.
7
Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.长期治疗期间人类免疫缺陷病毒1型对恩夫韦肽耐药的基因型和表型模式
Antimicrob Agents Chemother. 2004 Sep;48(9):3253-9. doi: 10.1128/AAC.48.9.3253-3259.2004.
8
Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.胆固醇化肽 HIV-1/2 融合抑制剂的设计与表征:具有极强和持久的抗病毒活性。
J Virol. 2019 May 15;93(11). doi: 10.1128/JVI.02312-18. Print 2019 Jun 1.
9
Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).靶向HIV-1 gp41的肽融合抑制剂:专利综述(2009 - 2014年)
Expert Opin Ther Pat. 2015 Feb;25(2):159-73. doi: 10.1517/13543776.2014.987752. Epub 2014 Nov 27.
10
HIVfird: A Tool for Detection of Resistance to Fusion Inhibitor Drugs in HIV-1 Sequences.HIVfird:一种用于检测HIV-1序列中融合抑制剂药物耐药性的工具。
AIDS Res Hum Retroviruses. 2019 Oct;35(10):941-947. doi: 10.1089/AID.2019.0116. Epub 2019 Aug 12.

引用本文的文献

1
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning.一种通过双特异性抗体介导的预定位作用具有增强的HIV-1中和能力的广谱抗体。
Nat Commun. 2025 May 18;16(1):4617. doi: 10.1038/s41467-025-60035-6.
2
Peptide-Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics.肽药物偶联物:下一代肽治疗药物的新兴方向。
J Med Chem. 2024 Feb 8;67(3):1641-1661. doi: 10.1021/acs.jmedchem.3c01835. Epub 2024 Jan 26.
3
The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles.

本文引用的文献

1
Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.重新探讨恩夫韦肽的作用机制,并通过针对 gp41 中的三个靶点设计一个类似物来提高融合抑制活性。
AIDS. 2019 Aug 1;33(10):1545-1555. doi: 10.1097/QAD.0000000000002208.
2
An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes.HIV-1 逃避广泛中和抗体的抗原图谱区分功能和结构表位。
Immunity. 2019 Feb 19;50(2):520-532.e3. doi: 10.1016/j.immuni.2018.12.017. Epub 2019 Jan 29.
3
Structural basis of coreceptor recognition by HIV-1 envelope spike.
治疗相关突变对 HIV 复制和传播周期的影响。
Viruses. 2022 Dec 30;15(1):107. doi: 10.3390/v15010107.
4
Mutational fitness landscape and drug resistance.突变适应性景观与耐药性。
Curr Opin Struct Biol. 2023 Feb;78:102525. doi: 10.1016/j.sbi.2022.102525. Epub 2023 Jan 6.
5
The endoplasmic reticulum proteostasis network profoundly shapes the protein sequence space accessible to HIV envelope.内质网蛋白质稳态网络深刻地塑造了 HIV 包膜可及的蛋白质序列空间。
PLoS Biol. 2022 Feb 18;20(2):e3001569. doi: 10.1371/journal.pbio.3001569. eCollection 2022 Feb.
6
HIV-1 capsid variability: viral exploitation and evasion of capsid-binding molecules.HIV-1 衣壳变异性:病毒对衣壳结合分子的利用和逃逸。
Retrovirology. 2021 Oct 26;18(1):32. doi: 10.1186/s12977-021-00577-x.
7
Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond.基于肽的融合抑制剂预防 I 类融合蛋白六螺旋束形成:HIV 及其他。
Curr HIV Res. 2021;19(6):465-475. doi: 10.2174/1570162X19666210908115231.
8
Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors.病毒糖蛋白及其宿主受体的深度突变扫描
Front Mol Biosci. 2021 Apr 9;8:636660. doi: 10.3389/fmolb.2021.636660. eCollection 2021.
9
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.直接作用抗病毒药物及其他药物的耐药性规避药物设计策略。
Chem Rev. 2021 Mar 24;121(6):3238-3270. doi: 10.1021/acs.chemrev.0c00648. Epub 2021 Jan 7.
10
Comprehensive fitness maps of Hsp90 show widespread environmental dependence.Hsp90 的综合适应图谱显示出广泛的环境依赖性。
Elife. 2020 Mar 4;9:e53810. doi: 10.7554/eLife.53810.
HIV-1 包膜刺突识别辅助受体的结构基础。
Nature. 2019 Jan;565(7739):318-323. doi: 10.1038/s41586-018-0804-9. Epub 2018 Dec 12.
4
Structural and functional characterization of HIV-1 cell fusion inhibitor T20.HIV-1 细胞融合抑制剂 T20 的结构与功能表征。
AIDS. 2019 Jan 27;33(1):1-11. doi: 10.1097/QAD.0000000000001979.
5
Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV.全面分析针对 HIV 融合肽的感染和疫苗诱导抗体的功能。
PLoS Pathog. 2018 Jul 5;14(7):e1007159. doi: 10.1371/journal.ppat.1007159. eCollection 2018 Jul.
6
HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.HIV-1 gp41 残基调节包膜糖蛋白中 CD4 诱导的构象变化和 gp120 构象的弛豫演化。
J Virol. 2018 Jul 31;92(16). doi: 10.1128/JVI.00583-18. Print 2018 Aug 15.
7
Mapping mutational effects along the evolutionary landscape of HIV envelope.绘制 HIV 包膜在进化景观中的突变效应图谱。
Elife. 2018 Mar 28;7:e34420. doi: 10.7554/eLife.34420.
8
The β20-β21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions.gp120的β20-β21是HIV-1包膜糖蛋白(Env)构象转变的调节开关。
Nat Commun. 2017 Oct 19;8(1):1049. doi: 10.1038/s41467-017-01119-w.
9
Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.HIV-1对一种广泛中和抗体逃逸的全面图谱分析
Cell Host Microbe. 2017 Jun 14;21(6):777-787.e4. doi: 10.1016/j.chom.2017.05.003. Epub 2017 Jun 1.
10
Complete mapping of viral escape from neutralizing antibodies.病毒对中和抗体逃逸的完整图谱
PLoS Pathog. 2017 Mar 13;13(3):e1006271. doi: 10.1371/journal.ppat.1006271. eCollection 2017 Mar.